| Biomarker ID | 518 |
| PMID | 20171670 |
| Year | 2010 |
| Biomarker | Prostate Health Index (phi) |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign Sample |
| Type of Biomarker | Diagnostic |
| Cohort | 2037 men were screened for prostate cancer, and 322 were reccomended for biopsy. Out of these, 74 men complied out of which, 3 had a total PSA of 2.5 to 10 ng/ml and nonsuspicious DRE. |
| Senstivity | 88.5% |
| Specificity | 64.9% |
| AUC | 0.77 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Beckman Coulter ACCESS® 2 immunoassay |
| Clinical | No |
| Remarks | p2PSA provides improved discrimination between prostate cancer and benign disease in screened men with a prostate specific antigen of 2.5 to 10 ng/ml and a negative digital rectal examination. phi = (p2PSA/fPSA) X sqrt(PSA) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | Others |